American Pharmaceutical supplier problems delay ceftriaxone

American Pharmaceutical Partners announced it doesn't expect to get approval for its version of ceftriaxone for injection soon, citing information the drug company received this week from a raw material supplier that was inspected by the Food and Drug Administration. Ceftriaxone is the generic form of Roche's Rocephin, a cephalosporin antibiotic.

- read this report from TheStreet.com for more

Suggested Articles

AbbVie snagged the option to license Harpoon’s anti-BCMA multiple myeloma candidate and the duo added up to six new targets to their discovery deal.

In this week's EuroBiotech Report, Bayer's heart failure drug clears phase 3 test, ABPI calls for more U.K. investment and GHO raises €975 million. 

In our EuroBiotech roundup this week, Azeria raises £32 million, Zealand delays phase 3 readout and Galapagos eyes early 2021 IPF futility analysis.